Streamline MedTech (Beijing) Co., Ltd
HomePage-BookMark-简体中文
  • Home
  • Who We Are
  • Services
  • Why Streamline
  • Resources
  • Contact Us

Resources

Regulatory Systems
Useful Links
News and Events

News and Events

China: Will the Asian Clinical Trial Boom Turn to Bust

As GlaxoSmithKline, Bristol-Myers Squibb and Novartis are embroiled in alleged bribery and data falsification in Asia, CROs will have to a take a hard look at whether their investments in the region will pay off as quickly as they once thought.”

http://www.outsourcing-pharma.com/Clinical-Development/Will-the-Asian-Clinical-Trial-Boom-Turn-to-Bust

Previous:India: Indian Supreme Court seeks more oversight of DCGI’s clinical trial approvals  Next:China: US FDA: $10M in CR to Add More Capacity in China for Inspections
版权所有 © 2014-2024 思澜医药
京ICP备14009238号-1

Streamline MedTech (Beijing) Co., Ltd

Telephone: +86 10 6253 0237

本站基于 米拓企业建站系统 7.3.0 搭建